Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis

Sarcopenia has a negative impact on the prognosis of patients with liver cirrhosis (LC). We investigated the significance of skeletal muscle volume and its changes in LC patients taking levocarnitine (L-carnitine). We retrospectively analyzed 51 LC patients taking L-carnitine from December 2012 to March 2019. Skeletal mass index was calculated as the left-right sum of the major x minor axis of psoas muscle at the third lumbar vertebra, divided by height squared (psoas muscle index [PMI]). Patients were classified into 2 groups (low and normal PMI) depending on PMI < 6.0 and < 3.4 cm(2)/m(2)for men and women, respectively. Changes in PMI per month during L-carnitine administration (Delta PMI/m) were calculated, and we classified the patients into 2 groups (severe and mild muscle atrophy) depending on Delta PMI/m below the lower quartile. We assessed overall survival (OS). At the start of L-carnitine administration, there were no significant differences in OS between groups with low and normal PMI. Multivariate analysis showed that Delta PMI/m (hazard ratio [HR], 0.007;P = .005) and L-carnitine administration period (HR, 0.956;P = .021) were significantly associated with OS. Patients with severe muscle atrophy had a significantly lower OS than those with mild muscle atrophy. There was the positive correlation relationship between Delta PMI/m and L-carnitine administration period. Among LC patients taking L-carnitine, progressive muscle volume loss was a predictor of poor prognosis. L-carnitine administration for longer may be able to prevent muscle volume loss and lead to a better prognosis in LC patients.